T790M Mutations Identified by Circulating Tumor DNA Test in Lung Adenocarcinoma Patients Who Progressed on First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors

Overview

Journal Lung India

Specialty Pulmonary Medicine

Date 2020 Jan 4

PMID 31898615

Citations 4

Authors

Vinodini Merinda

Gatot Soegiarto

Laksmi Wulandari

Affiliations

Soon will be listed here.

Abstract

Background: Plasma circulating tumor deoxyribonucleic acid (ctDNA) test is an alternative method to detect the T790M mutation. Compared to conventional tumor rebiopsy, ctDNA possesses several advantages including less invasive, faster, lower costs, and having minimal risk of complications for patients.

Objective: The main objective of the study is to identify the prevalence of T790M mutations in lung adenocarcinoma patients who progressed after tyrosine kinase inhibitors (TKIs) therapy using ctDNA examination.

Materials And Methods: This was a retrospective cohort study based on medical records of lung adenocarcinoma patients in the Oncology Outpatient Clinic of Dr. Soetomo General Hospital within the period of January 2017-June 2018. Patients who progressed after receiving first-line epidermal growth factor receptor-TKI (EGFR-TKI) undergone plasma ctDNA examination and genotyping using digital platforms (Droplet Digital™ PCR) method.

Results: In total, there were 39 patients who met the criteria for ctDNA testing. Thirty-three patients (84.6%) received first-line gefitinib, while the other six (15.4%) received erlotinib. The T790M mutations were detected in 46.2% of patients. In addition, EGFR common mutation in exon 19 and exon 21 were detected in 87.2% of patients. Median progression-free survival of patients receiving first-line gefitinib or erlotinib were both around 9 months and did not differ significantly.

Conclusions: CtDNA examination successfully detected T790M mutation in a certain proportion of lung adenocarcinoma patients who progressed after first-line EGFR-TKI without the need for difficult and invasive rebiopsy.

Citing Articles

Ruptured mediastinal mature teratoma with shigellosis empyema: A case report.

Ashuri M, Wati F, Febriani A, Wulandari L Int J Surg Case Rep. 2023; 102:107857.

PMID: 36621215 PMC: 9850029. DOI: 10.1016/j.ijscr.2022.107857.

Correlation with Spectral CT Imaging Parameters and Occult Lymph Nodes Metastases in Sufferers with Isolated Lung Adenocarcinoma.

Liu Y, Nie Y Contrast Media Mol Imaging. 2022; 2022:5472446.

PMID: 35833081 PMC: 9252699. DOI: 10.1155/2022/5472446.

Conformity of Fine Needle Aspiration Biopsy (FNAB) and Core Needle Biopsy (CNB) in peripheral lung tumor patients: A cross-sectional study.

Marhana I, Widianiti K, Kusumastuti E Ann Med Surg (Lond). 2022; 75:103423.

PMID: 35386804 PMC: 8977934. DOI: 10.1016/j.amsu.2022.103423.

Liquid biopsy for T790M mutation detection: A ray of hope?.

Mohan A, Mittal S Lung India. 2020; 37(1):1-2.

PMID: 31898612 PMC: 6961109. DOI: 10.4103/lungindia.lungindia_543_19.

References

Jenkins S, Yang J, Ramalingam S, Yu K, Patel S, Weston S . Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017; 12(7):1061-1070. DOI: 10.1016/j.jtho.2017.04.003. View

Socinski M, Villaruz L, Ross J . Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. Oncologist. 2016; 22(1):3-11. PMC: 5313265. DOI: 10.1634/theoncologist.2016-0285. View

Wang Z, Cheng Y, An T, Gao H, Wang K, Zhou Q . Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med. 2018; 6(9):681-690. DOI: 10.1016/S2213-2600(18)30264-9. View

Dela Cruz C, Tanoue L, Matthay R . Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011; 32(4):605-44. PMC: 3864624. DOI: 10.1016/j.ccm.2011.09.001. View

Wu Y, Zhou C, Hu C, Feng J, Lu S, Huang Y . Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(2):213-22. DOI: 10.1016/S1470-2045(13)70604-1. View

Cortot A, Janne P . Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev. 2014; 23(133):356-66. PMC: 9487318. DOI: 10.1183/09059180.00004614. View

Douillard J, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A . First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2013; 110(1):55-62. PMC: 3887309. DOI: 10.1038/bjc.2013.721. View

Berois N, Touya D, Ubillos L, Bertoni B, Osinaga E, Varangot M . Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population. J Cancer Epidemiol. 2017; 2017:6170290. PMC: 5506465. DOI: 10.1155/2017/6170290. View

Noronha V, Choughule A, Patil V, Joshi A, Kumar R, Philip D . Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. Onco Targets Ther. 2017; 10:2903-2908. PMC: 5476719. DOI: 10.2147/OTT.S133245. View

10.

Zheng D, Ye X, Zhang M, Sun Y, Wang J, Ni J . Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016; 6:20913. PMC: 4751431. DOI: 10.1038/srep20913. View

11.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

12.

Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge D . Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015; 13(5):515-24. DOI: 10.6004/jnccn.2015.0071. View

13.

Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K . EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. Lung Cancer. 2017; 113:37-44. DOI: 10.1016/j.lungcan.2017.08.021. View

14.

He C, Zheng L, Xu Y, Liu M, Li Y, Xu J . Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer. Clin Chim Acta. 2013; 425:119-24. DOI: 10.1016/j.cca.2013.07.012. View

15.

Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H . Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2012; 24(1):54-9. DOI: 10.1093/annonc/mds214. View

16.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

17.

Seki Y, Fujiwara Y, Kohno T, Yoshida K, Goto Y, Horinouchi H . Circulating cell-free plasma tumour DNA shows a higher incidence of mutations in patients with extrathoracic disease progression. ESMO Open. 2018; 3(2):e000292. PMC: 5812398. DOI: 10.1136/esmoopen-2017-000292. View

18.

Pirker R, Herth F, Kerr K, Filipits M, Taron M, Gandara D . Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010; 5(10):1706-13. DOI: 10.1097/JTO.0b013e3181f1c8de. View

19.

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

20.

Lee J, Qing X, Xiumin W, Yali B, Chi S, Bak S . Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget. 2016; 7(6):6984-93. PMC: 4872763. DOI: 10.18632/oncotarget.6874. View